S&P Futures
6,002.75 -1.00 (-0.02%) Dow Futures
43,901.00 -9.00 (-0.02%) Nasdaq Futures
21,223.25 -1.50 (-0.01%) Russell 2000 Futures
2,397.20 +1.50 (+0.06%) Crude Oil
71.89 -0.47 (-0.65%) Gold
2,704.10 -1.70 (-0.06%)
BioCryst Pharmaceuticals, Inc. (BCRX)
After hours:
| Previous Close | 7.73 |
| Open | 7.70 |
| Bid | 7.63 x 200 |
| Ask | 7.70 x 200 |
| Day's Range | 7.51 - 7.88 |
| 52 Week Range | 4.03 - 8.88 |
| Volume | |
| Avg. Volume | 1,952,811 |
| Market Cap | 1.601B |
| Beta (5Y Monthly) | 1.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.61 |
| Earnings Date | Nov 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.64 |
GlobeNewswireBioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2024 Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 5:00 a.m. ET.7th Annual Evercore HealthCONx Conference in Coral Gables on Wednesday, December 4, 2024, at 2:35 p.m. ET.Piper Sandler 36th Annual Healthcare Conference in New York on Thursday, December 5, 2024, at 8:30 a.m. ET. Lin
TipRanksBioCryst Announces Strong Q3 2024 Revenue Growth
BioCryst ( (BCRX) ) has issued an announcement. BioCryst Pharmaceuticals reported a strong Q3 2024 with ORLADEYO net revenue of $116.3 million, growing 35.7% year-over-year, and adjusted full-year revenue guidance to $430-$435 million. The company introduced additional revenue guidance of $443-$448 million including RAPIVAB and achieved a GAAP operating profit of $7.7 million. Advancements in their pipeline include BCX17725 for Netherton syndrome and avoralstat for DME, showcasing significant pr
